晚期人表皮生长因子受体2阳性乳腺癌的系统治疗:ASCO指南更新
美国临床肿瘤学会(ASCO)专家组针对HER2阳性晚期乳腺癌的系统治疗及中枢神经系统转移进行靶向系统文献综述,共识别545篇文章,其中14篇构成推荐证据基础。指南推荐HER2靶向治疗用于HER2阳性晚期乳腺癌(临床充血性心力衰竭或左心室射血分数显著降低者需个体化评估),一线推荐曲妥珠单抗+帕妥珠单抗+紫杉类,二线推荐曲妥珠单抗德鲁替康,三线应提供其他HER2靶向治疗组合。
要点
- HER2阳性晚期乳腺癌推荐HER2靶向治疗,但临床充血性心力衰竭或左心室射血分数显著降低者需个体化评估。
- 一线推荐曲妥珠单抗+帕妥珠单抗+紫杉类,二线推荐曲妥珠单抗德鲁替康。
- 三线应提供其他HER2靶向治疗组合;因缺乏头对头试验,证据不足以推荐某一方案优于另一方案。
核心结论
- HER2靶向治疗推荐用于HER2阳性晚期乳腺癌患者,但临床充血性心力衰竭或左心室射血分数显著降低者应个体化评估。
- 一线推荐曲妥珠单抗、帕妥珠单抗联合紫杉类,二线推荐曲妥珠单抗德鲁替康。
- 三线应提供其他HER2靶向治疗组合;因缺乏头对头试验,证据不足以推荐某一方案优于另一方案。
研究设计与样本
- ASCO专家组针对系统治疗及中枢神经系统转移进行靶向系统文献综述,共识别545篇文章。
- 其中14篇构成指南推荐的证据基础。
主要发现
- 共识别并审阅545篇文献,其中14篇构成指南推荐的证据基础。
- 关注的结局包括疗效和安全性。
关键数值与推荐
- HER2靶向治疗推荐用于HER2阳性晚期乳腺癌,除外临床充血性心力衰竭或左心室射血分数显著降低者,后者应个体化评估。
- 一线推荐曲妥珠单抗、帕妥珠单抗联合紫杉类;二线推荐曲妥珠单抗德鲁替康。
- 三线应提供其他HER2靶向治疗组合;可选方案包括含图卡替尼、曲妥珠单抗恩坦辛、曲妥珠单抗德鲁替康(若既往未使用)、奈拉替尼、拉帕替尼、化疗、马吉妥昔单抗、内分泌治疗、阿贝西利联合曲妥珠单抗及氟维司群的方案,若患者既往未接受帕妥珠单抗可考虑帕妥珠单抗。
- 化疗最佳持续时间为至少4-6个月或直至最大缓解,取决于毒性和无进展。
- HER2靶向治疗可持续至进展或不可接受毒性。
临床怎么用
- HER2阳性晚期乳腺癌推荐HER2靶向治疗,但临床充血性心力衰竭或左心室射血分数显著降低者应个体化评估。
- 一线推荐曲妥珠单抗、帕妥珠单抗联合紫杉类,二线推荐曲妥珠单抗德鲁替康。
- 三线应提供其他HER2靶向治疗组合;因缺乏头对头试验,证据不足以推荐某一方案优于另一方案。
- 患者与临床医生在决策过程中应讨论治疗方案、给药途径、毒性等方面的差异。
- HER2靶向治疗可持续至进展或不可接受毒性;化疗最佳持续时间为至少4-6个月或直至最大缓解,取决于毒性和无进展。
局限性
- 原文指出缺乏头对头试验,因此证据不足以推荐某一方案优于另一方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To update evidence-based guideline recommendations to practicing oncologists and others on systemic therapy for patients with human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer. METHODS: An Expert Panel conducted a targeted systematic literature review (for both systemic treatment and CNS metastases) and identified 545 articles. Outcomes of interest included efficacy and safety. RESULTS: Of the 545 publications identified and reviewed, 14 were identified to form the evidentiary basis for the guideline recommendations. RECOMMENDATIONS: HER2-targeted therapy is recommended for patients with HER2-positive advanced breast cancer, except for those with clinical congestive heart failure or significantly compromised left ventricular ejection fraction, who should be evaluated on a case-by-case basis. Trastuzumab, pertuzumab, and taxane for first-line treatment and trastuzumab deruxtecan for second-line treatment are recommended. In the third-line setting, clinicians should offer other HER2-targeted therapy combinations. There is a lack of head-to-head trials; therefore, there is insufficient evidence to recommend one regimen over another. The patient and the clinician should discuss differences in treatment schedule, route, toxicities, etc during the decision-making process. Options include regimens with tucatinib, trastuzumab emtansine, trastuzumab deruxtecan (if either not previously administered), neratinib, lapatinib, chemotherapy, margetuximab, hormonal therapy, and abemaciclib plus trastuzumab plus fulvestrant, and may offer pertuzumab if the patient has not previously received it. Optimal duration of chemotherapy is at least 4-6 months or until maximum response, depending on toxicity and in the absence of progression. HER2-targeted therapy can continue until time of progression or unacceptable toxicities. For patients with HER2-positive and estrogen receptor-positive or progesterone receptor-positive breast cancer, clinicians may recommend either standard first-line therapy or, for selected patients, endocrine therapy plus HER2-targeted therapy or endocrine therapy alone.Additional information is available at www.asco.org/breast-cancer-guidelines.
引用
- Giordano SH, Franzoi MAB, Temin S, et al. Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Guideline Update. J Clin Oncol. 2022. PMID: 35640077. doi:10.1200/JCO.22.00519
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。